Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: ALK
Name: ALK receptor tyrosine kinase
Location: 02p23.2-p23.1
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT00069238 Campath-1H and EPOCH to Treat Non-Hodgkins T- and NK-Cell Lymphomas View
NCT00082017 UCN-01 7-Hydroxystaurosporine to Treat Relapsed T-Cell Lymphomas View
NCT00408616 Efficacy and Safety of Grazax in Children View
NCT00773240 A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment View
NCT00907920 Studying Tumor Samples From Young Patients With Neuroblastoma View
NCT01795846 Evaluation of Immunological Changes and Clinical Efficacy of Specific Immunotherapy With Der p House Dust Mite Allergen in Polysensitized and Monosensitized Patients With Allergic Rhinitis andor Asthma View
NCT01061203 Grazax Asthma Prevention View
NCT01100151 ALK37-003 A Study of RDC-1036 ALKS 37 in Adults With Opioid-induced Constipation OIC View
NCT04227028 Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced Metastatic or Recurrent NSCLC View
NCT01454531 An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy View
NCT01535118 A Survey of Adults and Children With Allergic Rhinoconjunctivitis MK-7243-021 View
NCT04223596 Clinical Utility of Liquid Biopsy in Brigatinib ALK Patients View
NCT01596374 Clinical Relevance of ROS V-ros UR2 Sarcoma Virus Oncogene Homolog Aberrations in Solid Tumours View
NCT01829503 Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia AML View
NCT02013219 A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer NSCLC View
NCT03399487 A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement View
NCT02218008 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder MDD - FORWARD-5 Study View
NCT03766516 Registry of BrentuximabVedotinin Patients With RR Anaplastic Large Cell Lymphoma or Classical HL View
NCT02372448 Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients View
NCT02437786 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX View
NCT02521857 A Water Consumption Study of ALKS 5461 in Healthy Volunteers View
NCT02545439 A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers View
NCT03090815 Circulating Tumor DNA ctDNA as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma View
NCT02465528 Ceritinib Rare Indications Study in ALK Tumors View
NCT04513301 Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC EGFR - ALK - After Failure of Platinum-based Chemotherapy A RandomizedOpen Labled Phase II Clinical Study View
NCT02669758 A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia View
NCT00310453 Tolerability of ALK Grass Tablet in Children View
NCT02827344 PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer View
NCT02959619 Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK View
NCT03088930 Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer View
NCT03093116 A Study of Repotrectinib TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements View
NCT03178071 Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive View
NCT04260009 Pharmacokinetics Safety and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK Anaplastic Large Cell Lymphoma Inflammatory Myofibroblastic Tumors or Other Solid Tumors View
NCT04712877 Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers View
NCT05303064 Study to Evaluate Weight Gain As Assessed by Change in BMI Z-score in Pediatric Subjects with Schizophrenia or Bipolar I Disorder View
NCT03603184 Atezolizumab Trial in Endometrial Cancer - AtTEnd View
NCT03607188 Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer View
NCT03721120 Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer View
NCT03786692 Phase II Randomized Trial of CarboplatinPemetrexedBevacizumab- Atezolizumab in Stage IV NSCLC View
NCT03801304 Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer View
NCT03823625 An Open-label Randomized Parallel Non Comparative Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer SqLC View
NCT03919994 Observational Study of Long Acting Injectable Medications LAIs in Schizophrenia OASIS View
NCT04056572 Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase ALK Positive Non-Small Cell Lung Cancer NSCLC Previously Treated With Crizotinib View
NCT05713006 Alectinib Pharmacokinetic in Patients With NSCLC View
NCT06487078 Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context View
NCT04551521 CRAFT The NCT-PMO-1602 Phase II Trial View
NCT05881577 The Effect of Allergic Rhinitis on Educational Outcomes View
NCT04629027 Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC View
NCT01986595 A Pilot Study on ALK Gene Mutations in Neuroblastoma View
NCT04987229 Long-term Safety Extension Study of OLZSAM in Pediatric Subjects View
NCT05019105 Phase 1 ALKS 1140 in Healthy Adults View
NCT02005627 Grass Pollen Allergen Immunotherapy Tablet AIT Time Course Study View
NCT05178511 Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance View
NCT05557487 Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration View
NCT05655858 Observational Study of Allergic Rhinitis in Children View
NCT05801107 Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer NSCLC Patients View
NCT00330083 Safety of ALK Ragweed Tablet View
NCT02873208 A Phase 3 Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia View
NCT06196424 A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer FAHIC - Lung View
NCT02259114 A Dose-Finding Study of Birabresib MK-8628 a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal BET Proteins in Adults With Selected Advanced Solid Tumors MK-8628-003 View
NCT02679170 Study to IDEntify Patients With AdvancedMetastatic Non Small Cell Lung Cancer NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management IDEALKROS View
NCT01100840 A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer View
NCT03256136 Nivolumab in Combination With Chemotherapy or Nivolumab in Combination With Ipilimumab in Advanced EGFR-Mutant or ALK-Rearranged NSCLC View
NCT03727867 Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer View
NCT01124864 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy View
NCT03610048 A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder MDD View
NCT03833934 Study of Plasma NGS for Assessment Characterization Evaluation of Patients With ALK Resistance View
NCT01620853 Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer NSCLC Using Fluorescent in Situ Hybridization FISH ALK Test View
NCT01154140 A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung View
NCT00227279 A Trial of the ALK Grass Tablet in Subjects With Hayfever View
NCT04323436 Study of Capmatinib and SpartalizumabPlacebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations View
NCT03564197 18F-PD-L1 PETCT in Nivolumab Treated Patients With NSCLC View
NCT03087448 Ceritinib Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer NSCLC View
NCT01700192 Efficacy and Safety Study of SCH 900237MK-8237 in Children and Adults With House Dust Mite-Induced Allergic RhinitisRhinoconjunctivitis P05607 View
NCT02810262 Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer POUMOS View
NCT01662635 Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p EML4-ALK View
NCT02502240 ALK Rearrangements in Lung Adenocarcinoma Epidemiology in Latin America CLICaP View
NCT01385371 A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms With or Without Asthma P08067 View
NCT00298701 Tolerability of Grazax-R in Children View
NCT03093324 A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis RRMS EVOLVE-MS-2 View
NCT04425135 Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy Pemetrixed Carboplatin in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC View
NCT04427072 Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation View
NCT00421655 A Trial of Grazax in Subjects With Hayfever View
NCT01454544 A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet View
NCT00535639 Tolerability of ALK Tree Tablet View
NCT01500200 A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder MDD View
NCT04499794 The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring View
NCT01524926 CREATE Cross-tumoral Phase 2 With Crizotinib View
NCT01531361 Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations View
NCT00633919 Efficacy of SLITone in House Dust Mite Allergic Patients View
NCT04515979 Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer NSCLC Subjects View
NCT04547504 PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers NSCLC With PDL1 50 View
NCT02604342 Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase ALK-Positive Advanced Non-Small Cell Lung Cancer NSCLC Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib View
NCT01603056 Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis View
NCT00807547 Intraseasonal Short-time Up-dosing With Alutard SQ Grasses View
NCT01629719 Study Phase III Comparison of Superiority Open With Blind Appraiser to Evaluate the Efficacy and Safety of Barium Sulphate 667 With V OPTI-BAR Compared to Proceedings in Inert Radiological Examinations for the Diagnosis of Diseases for Image the Tratogastrointstinal View
NCT02694328 A Study of ALKS 3831 in Adults With Schizophrenia The ENLIGHTEN-2 Study View
NCT00857779 Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients View
NCT01634763 Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase ALK View
NCT02201992 Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations An ALCHEMIST Treatment Trial View
NCT02042105 A Prospective Epidemiologic Study of ALK-Positive NSCLC in China View
NCT02352948 A Global Study to Assess the Effects of MEDI4736 Durvalumab Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer View
NCT00939770 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma View
NCT04647110 Real-world Therapy of ALK-positive NSCLC in Sweden the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers View
NCT02314481 Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity View
NCT02230228 Phase 1 Safety Study of ALK-001 in Healthy Volunteers View
NCT01679860 Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma View
NCT01674595 An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy View
NCT01685138 LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer View
NCT01685060 LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib View
NCT02321501 Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer View
NCT02094573 A Study to Evaluate the Efficacy of Brigatinib AP26113 in Participants With Anaplastic Lymphoma Kinase ALK-Positive Non-small Cell Lung Cancer NSCLC Previously Treated With Crizotinib View
NCT04676360 Belantamab Mafodotin In Plasmablastic Lymphoma ALK Large B-Cell Lymphoma View
NCT01700582 French National Observatory of the Patients With Non-small Cell Lung NSCLC and Molecular Testings View
NCT02453282 Phase III Open Label First Line Therapy Study of MEDI 4736 Durvalumab With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer NSCLC View
NCT01728285 Compliance to the Treatment With GRAZAX Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis View
NCT01720173 Dalantercept in Treating Patients With Recurrent Ovarian Epithelial Fallopian Tube or Primary Peritoneal Cavity Cancer View
NCT01163058 Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer View
NCT02271139 Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase ALK-Rearranged Non-Small Cell Lung Cancer NSCLC After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy View
NCT02552901 Cardiox Liver Function Test Pivotal Trial View
NCT02336451 A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain andor to Leptomeninges View
NCT01245257 Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis View
NCT04764188 An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib View
NCT01740284 A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine View
NCT01257308 Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients View
NCT04777084 The Efficacy and Safety of the Bispecific Anti-PD-1PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC View
NCT01742286 Phase I Study of LDK378 in Pediatric Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase ALK View
NCT01283516 A Dose EscalationExpansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase View
NCT01752400 AUY922 for Advanced ALK-positive NSCLC View
NCT01284192 Study of an Investigational Drug ASP3026 in Patients With Advanced Malignancies Solid Tumors and B-Cell Lymphoma View
NCT02414139 Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type wt Advanced Non-small Cell Lung Cancer NSCLC Geometry Mono-1 View
NCT02301598 Femtosecond Laser-assisted Anterior Lamellar Keratoplasty View
NCT04806412 Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer A Prospective Study View
NCT02718651 Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer View
NCT01343420 Dog Hair Extract Study View
NCT02442414 A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors View
NCT01366170 Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma View
NCT01366001 ALK33BUP-101 Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine View
NCT02508506 Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function View
NCT02450903 LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib View
NCT01382797 ALK37-005 A Study of ALKS 37 RDC-1036 in Adults With Opioid-induced Constipation OIC View
NCT01772797 Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer View
NCT04837716 Ensartinib Carboplatin Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer View
NCT04844827 Pleural Carcinomatosis Tissue Banking View
NCT01418092 ALK37-007 Evaluation of Safety and Efficacy of ALKS 37 RDC-1036 in Adults With Opioid-induced Constipation OIC View
NCT02650401 Study Of Entrectinib Rxdx-101 in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors AndOr Who Have No Satisfactory Treatment Options View
NCT01425788 Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense View
NCT01433510 Tolerability of Grazax in Patients With Hayfever in Real Life Settings View
NCT03126916 Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma NBL View
NCT01626456 A Long-term Safety Study of ALKS 9072 Also Known as ALKS 9070 View
NCT01433523 House Dust Mite Treatment of Asthma The MITRA Trial House Dust Mite Treatment of Asthma View
NCT01449461 A Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase ALKEpidermal Growth Factor Receptor EGFR Inhibitor Brigatinib AP26113 View
NCT02402660 Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease View
NCT02706626 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors View
NCT01469039 A Study to Evaluate the Efficacy and Safety of ALKS 9072 Also Known as Aripiprazole Lauroxil ALKS 9070 or ARISTADA in Subjects With Schizophrenia View
NCT01469182 A Study of Ragweed Ambrosia Artemisiifolia Allergy Immunotherapy Tablet in Adults With Ragweed Allergies P05751 View
NCT04878354 A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis View
NCT01493726 A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia View
NCT04881461 A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis View
NCT02422589 A Phase I Multi-center Open Label Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors View
NCT01675791 A Dose-response Evaluation of ALK the Sponsor Tree Allergy Immunotherapy Tablet View
NCT03131206 A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer View
NCT02922426 An Insulin Sensitivity Study in Healthy Subjects View
NCT01568190 An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy View
NCT01562015 A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer NSCLC View
NCT01579994 Crizotinib and Ganetespib STA-9090 in ALK Positive Lung Cancers View
NCT04951817 68Ga-PSMA PETCT for Ra223 Assessment View
NCT01597258 Safety And Efficacy Of Crizotinib Regulatory Post Marketing Commitment Plan View
NCT02946359 AC in Metastatic Lung Adenocarcinoma Cancer View
NCT01639001 A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients View
NCT01637597 Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation View
NCT04997382 Immunochemotherapy or Chemotherapy in ALK-rearranged 5-ALK NSCLC View
NCT01644617 A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite HDM Induced Allergic RhinitisRhinoconjunctivitis in Adults MK-8237-003P07627 View
NCT05015010 Alectinib in Neo-adjuvant Treatment of Stage III NSCLC View
NCT01678807 Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents MK-8237-008 View
NCT00492076 Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma View
NCT01728298 A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy View
NCT05081674 Brazilian Lung Immunotherapy Study View
NCT00550550 Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents P05239 AM3COMPLETED View
NCT03130881 Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK NSCLC View
NCT05132218 Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer View
NCT01904916 CPCT-05 Biopsy Protocol Patient Selection View
NCT03311542 Expanded Access for Pembrolizumab MK-3475 View
NCT03321695 A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina View
NCT01887405 Comparative Evaluation of Handling Characteristics of Two Adrenaline AutoinjectorsEpiPen in Comparison With Jext View
NCT01895452 An Extension of a Long-term Safety Study of ALKS 9072 Also Known as ALKS 9070 View
NCT05200481 Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer MASTERPROTOCOL ALK View
NCT02511184 Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients View
NCT01930474 Analysis of Plasma Tumor DNA in Lung Cancer Patients View
NCT05236946 Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM A Phase III RCT View
NCT01947608 Expanded Treatment Protocol With LDK378 in ALK NSCLC View
NCT01801111 A Study of Alectinib RO5424802 in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase ALK Mutation and Failed Crizotinib Treatment View
NCT01970865 A Study Of PF-06463922 An ALKROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations View
NCT05257512 Phase III Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer View
NCT05266846 Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5ALK View
NCT03201757 Study to Evaluate the Long-term Safety Tolerability and Durability of Treatment Effect of ALKS 3831 View
NCT05296278 Efficacy and Biomarker Explanation of IBI-323 Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC View
NCT03213652 Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With ALK or ROS1 Genomic Alterations A Pediatric MATCH Treatment Trial View
NCT02048488 A Phase IIIa Open-Label Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas View
NCT03220230 Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients View
NCT02069535 An Open Trial to Assess the Tolerability of AVANZ Cupressus Immunotherapy View
NCT02075840 A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants View
NCT05378594 HDM and Silver Birch NAC Standardisation View
NCT02141399 A Long-Term Safety Study of ALKS 5461 View
NCT05384626 A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation ALKOVE-1 View
NCT02158533 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder MDD - the FORWARD-4 Study View
NCT02166268 Evaluation of the Efficacy and Safety of AVANZ Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber View
NCT02161718 A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder View
NCT02186821 Ceritinib LDK378 for Patients Whose Tumors Have Aberrations in ALK or ROS1 SIGNATURE View
NCT03271554 Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea View
NCT03410108 Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase ALK-Positive Non-Small Cell Lung Cancer NSCLC View
NCT02201849 A Study of ALKS 8700 a Monomethyl Fumarate MMF Molecule in Healthy Adults View
NCT02218021 A Study of the Abuse Liability Potential of Samidorphan in Healthy Non-Dependent Recreational Opioid Users View
NCT05441956 TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer NSCLC View
NCT03420508 Treating Patients With Melanoma and ALK Alterations With Ensartinib View
NCT03420742 A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Participants With ALK-Positive or ROS1-Positive Solid Tumors View
NCT02256553 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis P08607 MK-3641-006 View
NCT02277457 Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy PARTIST for Locally Advanced Non-small Cell Lung Cancer With Genomic Driver Mutations View
NCT02272764 A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers View
NCT02299505 Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With ALK-positive Metastatic Non-small Cell Lung Cancer NSCLC View
NCT05487391 A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection View
NCT02292550 Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer View
NCT02304406 Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East North Africa View
NCT05491811 Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation View
NCT02320032 An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia View
NCT03671538 Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin View
NCT03672643 Long Term Safety Observation of Crizotinib in Chinese NSCLC Population View
NCT05520853 SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC View
NCT05525338 Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels View
NCT03798743 Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC the SUCCESS Study View
NCT03505554 A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma View
NCT02374489 A Phase II Trial of LDK378 in ROS1 and or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma View
NCT02393625 Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer View
NCT01828099 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer View
NCT02419287 Pilot Study of Crizotinib in Relapsed ALK Lymphomas View
NCT02413281 A Study of the Abuse Liability Potential of ALKS 5461 in Healthy Non-Dependent Recreational Opioid Users View
NCT02469220 Diet Treatment of Patients With Ulcerative Colitis in Remission View
NCT02462538 Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK ALCL View
NCT02473497 Crizotinib Xalkori Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients View
NCT02479308 A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers View
NCT02481856 A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber View
NCT03707938 Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer View
NCT04211922 Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib View
NCT02502071 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes View
NCT02504463 A Study of 14c-Samidorphan Also Known as ALKS 33 in Healthy Male Volunteers View
NCT02513667 Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma View
NCT02521051 Phase III Trial of Alectinib and Bevacizumab in Patients With Advanced Anaplastic Lymphoma Kinase ALK-Positive Non-Small Cell Lung Cancer View
NCT02542293 Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer NSCLC NEPTUNE View
NCT03571360 CTA ExpressionMethylation and Response to Pembrolizumab of NSCLC Patients View
NCT02554591 Genomic Landscape of Ceritinib View
NCT02568267 Basket Study of Entrectinib RXDX-101 for the Treatment of Patients With Solid Tumors Harboring NTRK 123 Trk ABC ROS1 or ALK Gene Rearrangements Fusions View
NCT02572453 Phase 2 Study of AT13387 Onalespib in ALK ALCL MCL and BCL-6 DLBCL View
NCT03820154 Diagnostic Equivalence of the Skin Prick Test Tape vs Conventional Skin PrickTest View
NCT02584634 Study to Evaluate Safety Efficacy Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC Javelin Lung 101 View
NCT02584933 Roll-over Study to Allow Access to Certinib LDK378 for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study View
NCT02596321 A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis andor Atopic Asthma View
NCT05687266 Phase III Open-label First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations View
NCT02638909 Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies View
NCT02634320 A Study of Aripiprazole Lauroxil Also Known as ARISTADA TM in Subjects With Schizophrenia View
NCT02636842 A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder View
NCT02634307 A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis MS EVOLVE-MS-1 View
NCT02634346 A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia the ENLIGHTEN-1 Study View
NCT05718297 Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer View
NCT03611738 Ceritinib Plus Docetaxel in ALK-Negative EGFR WT Advanced NSCLC View
NCT05722886 DETERMINE Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial - Master Screening Protocol View
NCT05721950 A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer NSCLC View
NCT05724004 Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement A-SAB View
NCT02695550 Study of Safety Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer View
NCT02729961 Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma View
NCT04125888 Impact of AIT on Allergic Rhinitis and Asthma View
NCT05770037 DETERMINE Trial Treatment Arm 01 Alectinib in Adult TeenageYoung Adults TYA and Paediatric Patients With ALK Positive Cancers View
NCT02737501 ALTA-1L Study A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive ALK Advanced Non-small Cell Lung Cancer NSCLC Participants View
NCT02767804 eXalt3 Study Comparing X-396 Ensartinib to Crizotinib in ALK Positive Non-Small Cell Lung Cancer NSCLC Patients View
NCT01829217 Sunitinib in Never-Smokers With Lung Adenocarcinoma View
NCT02775006 Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type ALK Negative Non Squamous Cell Carcinoma View
NCT02799095 A Study of the Effects of ALKS 4230 Nemvaleukin Alfa on Subjects With Solid Tumors View
NCT02804568 A Phase 1 Safety Study in Adults With Schizophrenia View
NCT02804646 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma View
NCT03856411 A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC View
NCT02838420 A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase ALK-Positive Advanced Non-Small Cell Lung Cancer NSCLC View
NCT05845671 Amivantamab With Tyrosine Kinase Inhibitors TKI for Advanced NSCLC With ALK ROS1 or RET Alterations View
NCT01828112 LDK378 Versus Chemotherapy in ALK Rearranged ALK Positive Patients Previously Treated With Chemotherapy Platinum Doublet and Crizotinib View
NCT04541706 Lorlatinib in ALK Inhibitor Treated Unresectable AdvancedRecurrent ALK-Positive Non Small Cell Lung Cancer Patients in India View
NCT02868268 Neuroblastoma Precision Trial View
NCT03753685 X-396Ensartinib Capsules in ALK-Positive NSCLC Patients With Brain Metastases View
NCT04294810 A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer View
NCT04581824 Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer NSCLC View
NCT02927340 A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions View
NCT04317651 Crizotinib in ALK Rearranged Non-small-cell Lung Cancer View
NCT04318938 Advancing Brigatinib Properties in ALK NSCLC Patients by Deep Phenotyping View
NCT05948462 Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive ALK Non-small Cell Lung Cancer NSCLC Who Progressed on Single-agent Lorlatinib View
NCT03003962 Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer PEARL View
NCT04471428 Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1PD-1 Antibody and Platinum-Containing Chemotherapy View
NCT03052608 A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC View
NCT03066661 Expanded Access to Entrectinib for Cancers With NTRK123 ROS1 or ALK Gene Fusions View
NCT03083041 A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung CancerNSCLC View
NCT05991895 Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer View
NCT04362072 Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer View
NCT03107988 NANT 2015-02 A Phase 1 Study of Lorlatinib PF-06463922 View
NCT03136523 Tissue Microarrays TMAs Construction in Lung Cancer Samples View
NCT03155009 A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase ALK-Rearranged Non-Small Cell Lung Cancer View
NCT03164694 APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC View
NCT03188185 A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder MDD View
NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase ALK-Positive or Rearranged During Transfection RET-Positive Cancer View
NCT03202940 A Phase IBII Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged ALK NSCLC View
NCT03216863 Home Respiratory Rehabilitation in Advanced Lung Cancer Chemotherapy Per os View
NCT03215693 X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib View
NCT05482087 A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC View
NCT04423926 Lenalidomide in Combination With CHOP in Patients With Untreated PTCL View
NCT04541004 Adolescent Mite Allergy Safety Evaluation View
NCT03375437 RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK123 ROS1 or ALK Gene Fusions View
NCT04621188 Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC ALBATROS View
NCT01438827 Avanz Phleum Pratense Maintenance Dose View
NCT04800822 PF-07284892 in Participants With Advanced Solid Tumors View
NCT04900935 Patient-centered Optimal Integration of Survivorship and Palliative Care View
NCT04671849 An Open Label Multi-center Phase I Clinical Study to Evaluate the Safety Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally AdvancedMetastatic Solid Tumors With NTRK ROS1 or ALK Gene Fusion Mutations View
NCT03535740 A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive ALK Advanced Non-Small-Cell Lung Cancer NSCLC Progressed on Alectinib or Ceritinib View
NCT04677595 Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation View
NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC View
NCT04830124 Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 View
NCT03558165 Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay View
NCT06282536 Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC A Single Arm Exploratory Trial View
NCT04840004 Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer View
NCT03603847 Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma View
NCT03647111 Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer View
NCT03647488 Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer View
NCT03654976 Mite Asthma Pediatric Immunotherapy Trial View
NCT03707847 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK ALCL View
NCT06358950 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects with Narcolepsy Type 1 ALKS 2680-201 View
NCT03718117 Descriptive Observational Study ALK-2016-CPHG View
NCT03727477 Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib View
NCT03746860 NIS of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France View
NCT04880863 Naptumomab Estafenatox NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC View
NCT03764917 NGS Combined With RNAseq on Tumor Immune Escape in NSCLC View
NCT04881916 Immune and Genomic Markers in ALK NSCLC View
NCT03991403 Study of Atezolizumab Combination Carboplatin Paclitaxel Bevacizumab in EGRF Mutation or ALK Translocation NSCLC View
NCT06399926 Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir View
NCT03792568 ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation View
NCT06410040 A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK NSCLC Patients With Brain or Meningeal Metastasis View
NCT03837886 Effects of Sodium Bicarbonate Supplementation on Intermittent and Intense Task View
NCT03845582 Phase 3 Study of ALK-001 in Geographic Atrophy View
NCT05092360 Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer ARTISTRY-7 View
NCT03861793 A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 Nemvaleukin Alfa as a Single Agent and in Combination With Anti-PD-1 Antibody Pembrolizumab in Subjects With Select Advanced or Metastatic Solid Tumors ARTISTRY-2 View
NCT03866980 A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer View
NCT03868423 Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers View
NCT05100134 Managed Access Programs for LDK378 Ceritinib View
NCT05122806 Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC View
NCT00562068 Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I Stage II Stage III or Stage IV Peripheral T-Cell Lymphoma View
NCT04009317 Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase ALK Positive Non-Small Cell Lung Cancer NSCLC View
NCT04005144 Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer View
NCT06569420 Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC View
NCT04042558 A Study Evaluating Platinum-Pemetrexed-Atezolizumab -Bevacizumab for Patients With Stage IIIBIV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies View
NCT05144997 Lorlatinib Continuation Study View
NCT04074993 Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays View
NCT04084717 Study of Crizotinib for ROS1 and MET Activated Lung Cancer View
NCT04094610 A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK ROS1 OR NTRK1-3 Alterations View
NCT06550336 A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma PTCL View
NCT05380024 A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer View
NCT05160922 Crizotinib Continuation Clinical Study View
NCT05055232 A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer View
NCT04145219 House Dust Mite Allergy Trial In Children View
NCT04146571 Expanded Access to Ensartinib for Participants With ALK NSCLC View
NCT04144517 A Study of ALKS 4230 Nemvaleukin Alfa With Pembrolizumab in Head and Neck Cancer View
NCT01854736 Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate View
NCT04239625 Open-Label Extension Tolerability and Effects of ALK-001 on Stargardt Disease TEASE View
NCT04237805 A Phase III Clinical Study of SAF-189s in Non-small Cell Lung Cancer NSCLC Patients View
NCT05681780 Clinical Trial of CD40L-Augmented TIL for Patients With EGFR ALK ROS1 or HER2-Driven NSCLC View
NCT04292119 Lorlatinib Combinations in Lung Cancer View
NCT05711914 Predicting Response to PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging and Clinical Data View
NCT04351334 Anaplastic Lymphoma Kinase ALK-Positive Non-small Cell Lung Cancer NSCLC Post-alectinib Treatment Patterns View
NCT05735327 A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer NSCLC ENTIRETY View
NCT05740943 Induction Lorlatinib in Stage III Non-small Cell Lung Cancer View
NCT06586801 The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China View
NCT04415320 X-396 Ensartinib Capsules in ALK-Positive NSCLC Patients With Brain Metastases View
NCT03164616 Study of Durvalumab Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer POSEIDON View
NCT04439266 Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes MATCH-Subprotocol F View
NCT05765877 Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer View
NCT04459078 Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma View
NCT04459663 JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy View
NCT05782426 Study of Polymeric Micellar Paclitaxel Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC View
NCT04566432 Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients View
NCT04589013 Prediction of Response to Treatment With Immunotherapy Chemotherapy in Non-Small Cell Lung Cancer View
NCT01300429 Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus View
NCT04592653 Less Frequent IV Dosing Tumor Microenvironment TME Study of Nemvaleukin Alfa ALKS 4230 Monotherapy and in Combination With Pembrolizumab ARTISTRY-3 View
NCT05955391 TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer NSCLC View
NCT04624373 Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc View
NCT04634110 Brigatinib Before Brain Irradiation Trial B3i Trial View
NCT04632758 Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer NSCLC Patients View
NCT04640935 Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC View
NCT04641754 A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive or ROS1-positive Non-small Cell Lung Cancer View
NCT04644315 A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors View
NCT04708639 Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients View
NCT04706754 Pan-Canadian Lung Cancer Observational Study PALEOS View
NCT04777175 A Retrospective Study Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer View
NCT04774718 A Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors View
NCT00310492 Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis View
NCT06221670 Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations EGFR or ALK View
NCT06061848 Intralymphatic Immunotherapy Enhanced by Vitamin-D a Randomized Placebo-controlled Trial and Comparison With SLIT View
NCT04849273 A Study of TPX-0131 a Novel Oral ALK Tyrosine Kinase Inhibitor in Patients With ALK Advanced or Metastatic NSCLC View
NCT06074588 Sacituzumab Tirumotecan MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With EGFR Mutations or Other Genomic Alterations MK-2870-004 View
NCT06234579 Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC Galileo Project View
NCT06081270 Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer View
NCT04887519 A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase ALK Positive Metastatic Non Small Cell Lung Cancer NSCLC View
NCT06241807 Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC View
NCT04908059 Leukemic Phase of ALCL View
NCT04925609 Brigatinib in Pediatric and Young Adult Patients With ALK ALCL IMT or Other Solid Tumors View
NCT01871805 A Study of Alectinib CH5424802RO5424802 in Participants With Anaplastic Lymphoma Kinase ALK-Rearranged Non-Small Cell Lung Cancer NSCLC View
NCT04947683 Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil View
NCT04968002 Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer A Prospective Single Arm Single Center Phase II Clinical Study of Neoadjuvant Therapy View
NCT04979988 Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients View
NCT04987658 Phase 1 Study of OLZSAM in Pediatric Subjects With Bipolar I Disorder View
NCT04989322 Pembrolizumab Lenvatinib and Chemotherapy After TKIs in NSCLC View
NCT05014464 ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma View
NCT05020457 SI-B001 Combined With Chemotherapy in the Treatment of EGFRALK WT Recurrent or Metastatic NSCLC View
NCT05047250 A Study of Atezolizumab in High PD-L1 Expression Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer View
NCT05116618 Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant ALK- and ROS1-rearranged View
NCT06361589 Real World Study of Lolatinib for Advanced ALK NSCLC Patients View
NCT05167500 Efficacy Safety Study of Lorlatinib in ALKROS1 Metastatic NSCLC Patients With Compassionate Use Treatment View
NCT06180005 Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano INOND View
NCT05186506 A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer View
NCT05204628 A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib View
NCT06644313 Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB N2 Non-small Cell Lung Cancer NSCLC View
NCT06644495 Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib View
NCT05284539 Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFRALKROS1 Mutant Lung Cancer View
NCT01903837 A Study of ALKS 3831 in Adults With Schizophrenia View
NCT05351320 WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC View
NCT06652555 The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer a Real-world Study View
NCT06555783 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 View
NCT00733629 Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia View
NCT05440643 Peanut Sublingual Immunotherapy SLIT-Tablet for Treatment of Peanut Allergy View
NCT01911273 A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 A Monoclonal Antibody With Antiangiogenic Features In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer View
NCT05456256 A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma View
NCT05476484 Comparative Real World Effectiveness of SQ Sublingual Immunotherapy SLIT-Tablets vs Controls in Allergic Rhinitis and Asthma View
NCT01922583 AUY922 in Patient With Stage IV NSCLC View
NCT05489887 Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma View
NCT05498064 A Real World Study of Ensartinib in Advanced ALK-positive NSCLC View
NCT00293046 Assessment of Grazax Treatment Compliance View
NCT05547100 Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan View
NCT01945021 Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive ALK Negative Advanced NSCLC View
NCT05550376 Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia View
NCT02343679 Novartis PhII Ceritinib LDK378 in RR ALK Hem Malignancies View
NCT01964157 An Open-label Multicenter Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement View
NCT06522360 Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer BrightStar-2 View
NCT02898116 Phase 12 Study of Ensartinib and Durvalumab in ALK-rearranged Non-small Cell Lung Cancer View
NCT06528847 Adjuvant Benmelstobart for Stage IB Grade 3 Invasive Lung Adenocarcinoma View
NCT01994057 A Retrospective Study of EGFR-TKIsGefitinib Erlotinib and Osimertinib in NSCLC Patients Treatment View
NCT01998126 Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer View
NCT02010047 Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients View
NCT02034981 Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK MET or ROS1 View
NCT05769075 A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Alterations View
NCT05792644 Therapeutic Effect of Crizotinib for Rearrangement-negative High Phosphorylated ALK Patients View
NCT02041468 Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients View
NCT02040870 LDK378 in Adult Chinese Patients With ALK-rearranged ALK-positive Advanced Non-small Cell Lung Cancer NSCLC Previously Treated With Crizotinib View
NCT00932893 An Investigational Drug PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase ALK Gene View
NCT00932451 An Investigational Drug PF-02341066 Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase ALK Gene View
NCT06620835 Trial for Local Ablative Treatment LAT Optimization in Patients With Advanced Non-Small Cells Lung Cancer NSCLC Presenting an Anaplastic Lymphoma Kinase ALK Rearrangement Treated by Brigatinib View
NCT05869162 Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI View
NCT00978029 Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older Study P06081 View
NCT03737994 Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer View
NCT00987909 Exposure Chamber Trial With Cat Immunotherapy View
NCT05934045 Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma View
NCT05950139 Prophylactic Peptide Vaccine in Advanced ALK NSCLC View
NCT06643416 Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia View
NCT05987956 Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms View
NCT05987644 Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements View
NCT06007937 A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer View
NCT01098435 ALK33-101 A Study of RDC-0313 ALKS 33 in Adults With Binge Eating Disorder View
NCT06062810 Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms View
NCT06082635 TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer NSCLC View
NCT06092086 Lorlatinib as the First-line Treatment in China Advanced ALK NSCLC View
NCT06159790 A Study to Compare Efficacy Safety and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer NSCLC View
NCT06151938 Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX in House Dust Mite Allergic Rhinitis View
NCT06225427 Gilteritinib for the Treatment of ALK NSCLC View
NCT01240954 Comparison of Different Up-dosing Schedules With Osiris View
NCT06249854 Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer View
NCT06254599 A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC View
NCT06269133 Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line 1L Treatment of Advanced Non-Small Cell Lung Cancer NSCLC in Adult United States US Patients View
NCT06282874 Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases View
NCT06282991 A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled View
NCT06294561 TGRX-326 Pharmacokinetic Drug Interaction View
NCT06333899 Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion View
NCT06339554 Alectinib-induced Endocrine Toxicity View
NCT01381107 ALK33BUP-201 Safety and Tolerability Study of ALKS 33-BUP ALKS 5461 Administration in Subjects With MDD View
NCT06378892 A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer NSCLC With Exclusively Extracranial Disease Progression on Lorlatinib View
NCT06426511 ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC View
NCT06438367 TGRX-326 Pharmacokinetic Mass Balance View
NCT02065856 An Open Trial to Assess the Tolerability of AVANZ Salsola Immunotherapy View
NCT00026910 Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkins Lymphoma View
NCT02085135 A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder MDD View
NCT00770315 Efficacy and Long-Term Safety of Ragweed Ambrosia Artemisiifolia Sublingual Tablet SCH 39641 in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma Study P05234 View
NCT02097810 Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1 NTRK2 NTRK3 ROS1 or ALK Molecular Alterations View
NCT01228435 IPI-504 in NSCLC Patients With ALK Translocations View
NCT02068105 A Study of ALKS 5461 in Healthy Volunteers View
NCT01642082 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer View
NCT01191359 Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch View
NCT00783198 Efficacy and Long-Term Safety of Ragweed Ambrosia Artemisiifolia Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma Study P05233COMPLETED View
NCT04176185 A Research Study in Chinese People With Allergy to House Dust Mites Using an Environmental Exposure Chamber View
NCT01401504 Study of an Investigational Drug ASP3026 in Patients With Solid Tumors View
NCT02134912 S1300 Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib View
NCT05241028 Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer View
NCT03944772 Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy ORCHARD View
NCT02158546 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder MDD - the FORWARD-3 Study View
NCT01625234 Phase 12 Study of X-396 an Oral ALK Inhibitor in Patients With ALK-positive Non-Small Cell Lung Cancer View
NCT05341583 Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase ALK Positive Non-small Cell Lung Cancer View
NCT03971305 A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK ALCL View
NCT01121588 An Investigational Drug Crizotinib PF-02341066 Is Being Studied In Tumors Except Non-Small Cell Lung Cancer That Are Positive For Anaplastic Lymphoma Kinase ALK View
NCT02171286 The Oncopanel Pilot TOP Study View
NCT00413556 Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets View
NCT01549340 Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy MK-7243-022 View
NCT02227940 Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer View
NCT02228421 Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients View
NCT01500824 A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase ALK Positive Advanced Non-Small Cell Lung Cancer View
NCT01548144 Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer View
NCT02784158 An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer View
NCT04111705 Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer View
NCT05361564 A Window of Opportunity Study for Investigating Drug Tolerant Persister DTP to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer NSCLC Harboring ALK Fusions View
NCT05370469 Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies View
NCT05444712 Transplantation After Complete Response In Patients With T-cell Lymphoma View
NCT02289144 Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer View
NCT02314364 A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC View
NCT00310466 Efficacy and Safety Trial of SLIToneTM Birch in Subjects With Hayfever View
NCT02452801 Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function View
NCT00389363 Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects View
NCT00562159 Efficacy and Safety of Grass Sublingual Tablet in Adults P05238 AM3COMPLETED View
NCT00585195 A Study Of Oral PF-02341066 A C-MetHepatocyte Growth Factor Tyrosine Kinase Inhibitor In Patients With Advanced Cancer View
NCT02487316 A Study of Treatment ALK Systemic Anaplastic Large Cell Lymphoma With Crizotinib View
NCT02605746 Preoperative Ceritinib LDK378 in Glioblastoma Multiforme and CNS Metastasis View
NCT02727335 Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements View
NCT02708667 An Observational Research Of Crizotinibs Hepatic Toxicity In Non-small Cell Lung Cancer Patients View
NCT02902874 Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ALCL ALK View
NCT02924402 Study to Evaluate Safety and Tolerability of XmAb13676 Plamotamab in Patients With CD20-expressing Hematologic Malignancies View
NCT02965885 A Study of TAS-116 in Patients With Solid Tumors View
NCT03042221 Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR ALK ROS1 or BRAF TKI Therapy View
NCT03187769 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia Schizophreniform or Bipolar I Disorder View
NCT03236675 Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients View
NCT03386929 Survival Prolongation by Rationale Innovative Genomics View
NCT03417882 GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1 NSCLC View
NCT03436056 PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients View
NCT03456076 A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer View
NCT03546894 A Study to Determine Progression-free Survival PFS and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive ALK Non-Small Cell Lung Cancer NSCLC Treated With Anaplastic Lymphoma Kinase ALK Inhibitors View
NCT03563716 A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer View
NCT03576937 Achieving Value in Cancer Diagnostics Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study View
NCT03631706 M7824 Versus Pembrolizumab as a First-line 1L Treatment in Participants With Programmed Death-ligand 1 PD-L1 Expressing Advanced Non-small Cell Lung Cancer NSCLC View
NCT03719898 Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma View
NCT03703050 Nivolumab for Pediatric and Adult RelapsingRefractory ALK for Evaluation of Response in Patients With Progressive Disease Cohort 1 or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse Cohort 2 View
NCT03778138 Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC View
NCT03775486 Study of DurvalumabOlaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer ORION View
NCT03779191 Alectinib in Combination With Bevacizumab in ALK Positive NSCLC View
NCT03790228 Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC View
NCT03909971 A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China View
NCT03917043 APG-2449 in Patients With Advanced Solid Tumors View
NCT03926260 Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA View
NCT04030429 Crizotinib in c-MET Mutation MetastaticRecurrentPersistent Endometrial Cancer View
NCT04087473 Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC View
NCT04127110 Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients View
NCT04139317 Safety and Efficacy of Capmatinib INC280 Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 50 View
NCT04151342 CAnadian CAncers With Rare Molecular Alterations CARMA - Basket Real-world Observational Study BROS View